Here’s a ray of hope from the American Cancer Society (ACS): Its recently released annual Cancer Statistics report noted that the five-year relative cancer…
Myeloma
Yesterday morning, I burned the toast. It wasn’t just a little, either. It was blackened to a crisp and set off the smoke alarm with…
Johnson & Johnson is now seeking regulatory approval in the European Union for Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for…
We’re nearly two weeks into the new year and I’m wondering, how are your resolutions going? If your answer is, “Not so well,” take heart…
There is a specific kind of silence that occurs only when there is bad news. This type of silence isn’t peaceful or calm. It is…
Medications designed to block a signaling protein called NOTCH3 — which plays a key role in the function and survival of cells in the body…
I’m writing this a few days after the end of ASH 2025, the annual meeting of the American Society of Hematology. As I mentioned…
VV169, an experimental cellular therapy being developed by Vyriad to treat myeloma, is expected to enter clinical testing in 2026, the…
This morning, while I was making myself a cup of coffee, I saw my reflection in the curved, stainless steel surface of the kettle as…
Johnson & Johnson (J&J) is asking the U.S. Food and Drug Administration (FDA) to approve a combination of two medications, Tecvayli (teclistamab) and…
